Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04448756 · ClinicalTrials.gov registry record · Phase 2
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT04448756 is a Phase 2 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 149 participants.
The verdict
NCT04448756, a Phase 2 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
Interventions
- DRUG Placebo
- DRUG M5049
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2021-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04448756
The ClinicalTrials.gov registry entry for NCT04448756 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04448756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04448756 about?
NCT04448756 is a clinical study titled "Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)". The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
What is the current status of trial NCT04448756?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2020-07-29. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT04448756?
The interventions under investigation include: Placebo (DRUG), M5049 (DRUG).
Who is sponsoring clinical trial NCT04448756?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.